Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Neutral +6

Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative

AI-generated analysis

📰 President Donald Trump announced a deal with Regeneron on Thursday, April 23, 2026, to lower the cost of pharmaceutical products under the White House’s most-favored-nation initiative.

💊 Regeneron agreed to reduce prices for all current and future drugs available through Medicaid as part of the agreement.

📉 The deal also includes selling cholesterol drug Praluent for $225 on the TrumpRx discounted drug website.

🗳️ The administration touted these deals as economic relief ahead of November’s midterm elections amid high health care costs straining budgets.

🏆 Regeneron is the final major pharmaceutical company to strike such a most-favored-nation deal after letters were sent to 17 companies last July.

🎤 Trump announced the discount initiative in an Oval Office event attended by HHS Secretary Robert F. Kennedy Jr. and CMS administrator Dr. Mehmet Oz.

🏥 During his first term in 2020, Trump received a dose of Regeneron’s antibody-testing drug while hospitalized for COVID-19.

💰 As part of the new arrangement, Regeneron committed to spending $27 billion in U.S. research, development, and manufacturing.

🧬 Regeneron announced FDA approval for Otarmeni, a gene therapy for congenital hearing loss, available at no charge to clinically eligible patients.

⚖️ The FDA approval for Otarmeni received expedited status under the Commissioner’s National Priority Voucher program, which is under congressional scrutiny.

🔍 Details of the drug pricing agreements have not been fully made public despite pressure from Congress to share contracts.

📜 Health Secretary Robert F. Kennedy Jr. stated his team would release non-proprietary details while urging Congress to codify deals into law.

⚠️ Previous deals with weight-loss drugmakers Eli Lilly and Novo Nordisk faced roadblocks when Medicare delayed program implementation earlier in the week.

🏛️ Most Americans have insurance coverage through work, individual markets, or government programs like Medicaid and Medicare that shield them from much of the cost.

🤝 Lower drug prices on Medicaid could help state budgets that fund the programs, despite patients already paying nominal co-payments.

Bullish Signals
  • Regeneron has agreed to lower the prices of all its current and future drugs on Medicaid as part of a deal announced by President Donald Trump.
  • As part of the agreement, Regeneron will sell its cholesterol drug Praluent for $225 on the White House's discounted drug website TrumpRx.
  • The deal represents one of many most-favored-nation agreements aimed at bringing U.S. pharmaceutical prices to levels comparable to other developed nations.
  • Regeneron has committed to spending $27 billion in research, development, and manufacturing within the United States as part of the arrangement.
  • Regeneron's new gene therapy Otarmeni for congenital hearing loss received FDA approval and will be made available at no charge to clinically eligible individuals in the U.S.
  • The Otarmeni therapy received expedited approval from the FDA under the agency's Commissioner's National Priority Voucher program.
  • Lower drug prices on Medicaid could help state budgets that fund these programs by reducing costs for patients who already pay nominal co-payments.
Risk Factors
  • The most-favored-nation deals lack transparency as details of the agreements have not been made public despite being pressed by members of Congress.
  • A key agreement with weight-loss drugmakers Eli Lilly and Novo Nordisk fell apart earlier this week when Medicare delayed implementation of a program for insurers to cover GLP-1 drugs.
  • The FDA voucher program used for expedited approval has been under scrutiny from Democrats in Congress, who have noted the vouchers repeatedly go to companies agreeing to pricing concessions sought by the White House.
  • The deal involves selling cholesterol drug Praluent for $225 on TrumpRx, but it remains unclear how this discounted price compares to standard market pricing without public contract details.
  • President Trump's reliance on political optics suggests he is prioritizing midterms over long-term drug access reform, potentially undermining sustainable policy changes.
  • Regeneron's commitment of $27 billion in R&D spending for the U.S. may not offset potential revenue losses from mandatory price cuts if similar deals are extended across the industry.
Full Analysis
President Donald Trump announced a new agreement with drugmaker Regeneron on Thursday, April 23, 2026, at a White House event on health care affordability in the Oval Office. The deal requires Regeneron to lower prices for all current and future drugs under Medicaid programs as part of the administration’s broader most-favored-nation initiative. Additionally, Regeneron agreed to sell its cholesterol drug Praluent for $225 on the White House’s discounted drug website, TrumpRx. According to a White House fact sheet confirmed by NOTUS, this follows an earlier outreach effort last July when Trump sent letters to 17 major pharmaceutical companies, marking Regeneron as the final one to sign such an agreement before the upcoming November midterm elections. In conjunction with the price reductions, Regeneron committed to spending $27 billion in research, development, and manufacturing within the United States, a condition historically tied to relief from Trump tariffs. During the announcement, President Trump highlighted his past connection to the company, noting he received Regeneron’s investigational drug during his 2020 COVID-19 hospitalization and publicly praised the manufacturer shortly after recovering. The administration also revealed that Regeneron’s new gene therapy, Otarmeni, approved by the FDA for a rare form of congenital hearing loss, would be provided free to clinically eligible individuals in the U.S. This specific approval utilized an expedited pathway under the Commissioner’s National Priority Voucher program, which critics note has received scrutiny from Democrats as vouchers appear to consistently favor companies making pricing concessions requested by the White House. While Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare & Medicaid Services administrator Dr. Mehmet Oz attended the event alongside Commerce Secretary Howard Lutnick, the details of such agreements have not been fully made public. Pressed by Congress for transparency, Mr. Kennedy stated his team would share non-proprietary details but that Trump and himself are urging lawmakers to codify these deals into law. The administration frames these actions as transformative efforts to provide economic relief to Americans facing high costs for health care and other essentials, though some past initiatives involving weight-loss drugmakers like Eli Lilly and Novo Nordisk have encountered delays or failures due to Medicare implementation hurdles.